Reuters logo
BRIEF-XBiotech announces agreement with Cedars-Sinai Medical Center to evaluate MABP1 combination for the treatment of pancreatic cancer
September 20, 2017 / 12:16 PM / 3 months ago

BRIEF-XBiotech announces agreement with Cedars-Sinai Medical Center to evaluate MABP1 combination for the treatment of pancreatic cancer

Sept 20 (Reuters) - Xbiotech Inc

* Xbiotech announces agreement with Cedars-Sinai Medical Center to evaluate MABP1 in combination with Onivyde and 5-fluorouracil/folinic acid for the treatment of pancreatic cancer Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below